FHTX
Foghorn Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.21
+3.52%Year over year
Reported trailing growth
- Revenue
- +52.0%
- EBITDA
- +23.3%
- EBIT
- +25.5%
- EPS
- +17.5%
- Free cash flow
- +6.5%
- Operating cash flow
- +5.7%
Forward estimates
Based on analyst estimates
- Revenue
- -67.2%
- EBITDA
- +3.0%
- EPS
- +11.4%
Three-year CAGR
- Revenue
- +17.1%
- EBITDA
- +27.0%
- EBIT
- +20.0%
- Net income
- +14.2%
- EPS
- +25.3%
- Free cash flow
- +15.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026